Krebs Biochemicals & Industries Ltd Share Price Today - Krebs Biochemicals & Industries Ltd Stock Price Live NSE/BSE

Krebs Biochemicals & Industries Ltd

NSE: KREBSBIO BSE: 524518

₹59.67

(-0.55%)

Sat, 02 May 2026, 00:57 am

MTF 5xInvest in Krebs Biochemicals & Industries Ltd with 5x Leverage Buy with MTF

Market Cap1.23B

PE Ratio0

Dividend0

24.5K

Krebs Biochemicals & Industries Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
129.62
Net Profit
-26.94
P/B
-0.98
Sector P/E
41.71
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.17
Interest Cover (Industry)
18.19
ROCE (Industry)
20.67
RONW (Industry)
17.71
ROE
0
ROCE
0
Debt/Equity
0
EPS (TTM)
0
Dividend Yield
0
Book Value
-74.60
Interest Cover
-3.55

Analysis

all

Pros

The tenure for the Krebs Biochemicals & Industries board of directors is about average.
Avinash's compensation has been consistent with company performance over the past year, both up more than 20%.
KREBSBIO outperformed the Market in India which returned -14.5% over the past year.
NSEI:KREBSBIO is up 11.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
NSEI:KREBSBIO is up 11.8% outperforming the market in India which returned 8% over the past month.

Cons

Unable to evaluate Krebs Biochemicals & Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Krebs Biochemicals & Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
Krebs Biochemicals & Industries's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Krebs Biochemicals & Industries has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.9% each year.
Krebs Biochemicals & Industries has less than a year of cash runway based on current free cash flow.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	72.74	72.74	72.74	72.74	72.74
FII	0.49	0.49	0.49	0.49	0.49
DII	0	0	0	0	0
Public	26.77	26.77	26.77	26.77	26.77
Government	0	0	0	0	0

Technical Analysis

RSI

55.55

MACD

1.74

50 DMA

55.40

200 DMA

66.74

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	82.32	63.67	51.71	45.02	33.06	26.37	7.72
Fibonacci	63.67	56.55	52.14	45.02	37.90	33.49	26.37
Camarilla	44.88	43.17	41.46	45.02	38.04	36.33	34.62

Pivots Level: Classic

+37.30

82.32

+18.65

63.67

+6.69

51.71

45.02

Pivot Point

LTP: 59.67

-11.96

33.06

-18.65

26.37

-37.30

7.72

Moving Average

SMAEMA

Period

Value

10-EMA
59.64
20-EMA
58.26
30-EMA
57.39
50-EMA
57.29
100-EMA
59.84
200-EMA
65.26

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results, Nine Months Results
04 Nov 2025	board-meetings	Quarterly Results
28 Aug 2025	agm
30 Aug 2024	agm
20 Aug 2023	agm	Annual General Meeting	21 Sept 2023
09 Aug 2023	agm
21 Sept 2022	agm
23 Oct 2021	egm
31 Aug 2021	agm
15 Aug 2021	agm	Annual General Meeting	17 Sept 2021

Krebs Biochemicals & Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Cipla Ltd

Krebs Biochemicals & Industries Ltd About

Krebs Biochemicals & Industries is engaged in the business of manufacture of active pharmaceutical ingredients.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1991

Headquarters

CEO

R T Ravi

Employees

Contact

Website

http://www.krebsbiochem.com

investors@krebsbiochem.com; avinashr@krebsbiochem.

Phone

91-040-6680 8040

Location

Kothapalli(V) Kasimkota(M), Anakapalli, Vishakapatnam, Andhra Pradesh, 531031

Year	History
2007	Krebs Biochemicals designed an E-mail ID for Investor Complaints: [email protected]
2009	The Registered Office of the Company was shifted to 8-2-277/A, Plot No.130 , 4A, 4th Floor, Inwinex Towers, Road no.2, Banjara Hills, Hyderabad - 500034.
2014	The transfer agents of the Company were changed from Sathguru Management Consultants Pvt. Ltd to Karvy Computershare Pvt. Ltd. Mr. R.Ch. Satyanarayana was appointed as Independent Director on the Board.
2016	The company shifted its registered office from Plot No.34, 8-2-577/B, 3rd Floor, Maas Heights, Road No.8, Banjara Hills, Hyderabad, Telangana- 500034 to Kothapalli Village, Kasimkota Mandal, Anakapalli, Vishakapatnam, Andhra Pradesh- 531031.
2019	The company issued rights shares of Rs. 10 in the ratio of 21:100 at a premium of Rs. 76 per share.

Client Name	Order Side	QTY	Avg Price	Date
GUTTIKONDA RAJASEKHAR	Buy	143843	115.85	26 Nov 2024
N.G.C.S. (P) LTD.	Buy	117638	115.39	19 Jul 2024
N.G.C.S. (P) LTD.	Sell	117638	115.52	19 Jul 2024
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	371224	115.16	19 Jul 2024
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	371224	114.96	19 Jul 2024
BRESCON VENTURES PRIVATE LIMITED	Sell	225000	149.07	13 Aug 2021
BRESCON VENTURES PRIVATE LIMITED	Sell	100000	137.75	28 Dec 2020
RACHANADEVI RAJU AGARWAL	Sell	91270	90	13 Oct 2017
NATIONAL ISURANCE CO LTD	Sell	56563	20.02	02 Jul 2014
ANAPOTHANA VEMA TRUST	Sell	71730	9.5	03 May 2013

Krebs Biochemicals & Industries Ltd News

Krebs Biochemicals clarifies no material events

Krebs Biochemicals & Industries Limited responds to BSE inquiry about price movement, stating no material information requiring disclosure under SEBI regulations.

10 Apr 2026

companies

Krebs Biochemicals Files Q4FY26 Compliance Certificate

Krebs Biochemicals & Industries Limited submits mandatory SEBI Regulation 74(5) certificate for quarter ended March 31, 2026, confirming compliance with depositories regulations through registrar KFIN Technologies.

07 Apr 2026

companies

Krebs Biochemicals Reports Q3FY26 Loss of ₹312.65 Lacs

Krebs Biochemicals & Industries posted a net loss of ₹312.65 lacs for Q3FY26, with revenue declining 36.55% YoY to ₹727.42 lacs. Manufacturing operations remain closed due to pollution board orders.

09 Feb 2026

co actions results

Krebs Biochemicals Reports Loss of Rs 1,146.73 Lacs for Half-Year Ended September 2025

Krebs Biochemicals Industries Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported a loss before tax of Rs 1,146.73 lacs for the half-year period, compared to a loss of Rs 2,093.20 lacs in the corresponding period last year. Revenue from operations stood at Rs 1,977.70 lacs for the half-year. The company's cash and cash equivalents decreased to Rs 12.71 lacs as of September 30, 2025, from Rs 14.16 lacs at the beginning of the year. Net cash flow from operating activities was negative at Rs 167.56 lacs. The Board of Directors approved these results in a meeting held on November 4, 2025. The company operates in a single business segment and has no subsidiaries, associates, or joint venture companies.

04 Nov 2025

earnings

Krebs Biochemicals Shareholders Approve All Nine Resolutions at 33rd AGM

Krebs Biochemicals & Industries Limited held its 33rd Annual General Meeting on September 26, 2025, where all nine resolutions were passed by the required majority. Key approvals included adoption of audited financial statements for the year ended March 31, 2025, re-appointment of directors Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya who retired by rotation, and appointment of statutory auditors. Shareholders also approved the appointment of Mr. Manish Kumar Jain as Director and subsequently as Managing Director and CEO. Other resolutions covered related party transactions with Ipca Laboratories Limited, ratification of cost auditors' remuneration, and appointment of DSMR & Associates as secretarial auditors for five years starting from financial year 2025-26. The company has 9,111 shareholders on record date, with 31 shareholders attending the meeting either in person or through proxy.

27 Sept 2025

corporate governance

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800